Tiziana Life Sciences chief medical officer Matthew Davis joins Proactive's Natalie Stoberman to share the latest results from its intranasal foralumab study that's been published in Proceedings of the National Academy of Sciences (PNAS).
Davis says the results show how intranasal foralumab has had similar immune gene expression effects in COVID patients, MS patients and in heathy volunteers that were included in the study. From this study, Davis adds that intranasal foralumab could have a wider opportunity as a treatment for other inflammatory human diseases.
Proactive US
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.91 |
| Daily Change: | 0.11 14.19 |
| Daily Volume: | 30,471,781 |
| Market Cap: | US$94.480M |
January 23, 2025 January 22, 2025 January 10, 2025 January 08, 2025 December 17, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
